Purchase this article with an account.
Raul Velez-Montoya, Jeffrey Olson, Mark Petrash, Wells Messersmith, Naresh Mandava, Scott C. Oliver; Acute Onset Central Serous Retinopathy In Association With Mek Inhibitor Use For Metastatic Cancer. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2153.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe de characteristics and evolution of a group of patients, whom developed CSR after being treated with MEK/ERK inhibitors from different research trial.
Case report. Three elderly patients (2 female, 1 male), each one previously diagnosed with different malignancies, developed a wide range of visual symptoms, after being enrolled on different MEK/ERK inhibitors clinical trials
The three patients were diagnosed with CSR (one of them multifocal). All episodes were resolved a few days after patients stopped taking the drug and returned to baseline vision without complications or the need of further treatment
The patients currently under treatment with MEK/ERK inhibitors should be instructed about the possibility of developing CSR and its benign and self-limited nature. A well instructed population could improve the protocols compliance and decrease the withdraws due to inspected visual symptoms
This PDF is available to Subscribers Only